ANNOVIS BIO INC. COMMON STOCK

Annovis Announces New Publication in a Peer-Reviewed Journal

21 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results

13 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

06 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease

29 Apr 2024 10:10:00 By Nasdaq GlobeNewswire

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

02 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans

01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease

20 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease

14 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio

30 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement

24 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio to Participate in the 139th Yale CEO Summit

11 Dec 2023 13:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease

05 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Appoints Andrew Walsh as Vice President Finance

01 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections

27 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

08 Nov 2023 17:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study

12 Oct 2023 08:02:38 By Nasdaq GlobeNewswire

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans

27 Apr 2023 07:00:00 By Nasdaq GlobeNewswire